Premium
Detection of auto‐antibodies against L‐myc oncogene products in sera from lung cancer patients
Author(s) -
Yamamoto Akiyoshi,
Shimizu Eiji,
Ogura Takeshi,
Sone Saburo
Publication year - 1996
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(19960822)69:4<283::aid-ijc8>3.0.co;2-t
Subject(s) - antibody , lung cancer , oncogene , cancer , western blot , medicine , lung , carcinoma , cancer research , immunology , biology , pathology , gene , cell cycle , biochemistry
Auto‐antibodies against L‐ myc oncogene products (L‐Myc) in sera from lung cancer patients were examined using bacterially synthesized glutathione S‐transferase (GST) L‐Myc fusion proteins and Western blot analysis. The detection rate of anti‐L‐Myc antibodies in sera from lung cancer patients was 10%, while that in sera obtained from normal volunteers was 0%. Five patients with non‐small‐cell lung cancers (2 adenocarcinomas, 2 squamous‐cell carcinomas and 2 large‐cell carcinoma) were included in the group with anti‐L‐Myc antibodies. These auto‐antibodies belonged to the IgG class and recognized the carboxy terminus of L‐Myc. Circulating L‐Myc was not detected in sera from patients with anti‐L‐Myc antibodies. Differences in age, sex, performance status, histology, stage, smoking history and prior treatment were not significantly different between anti‐L‐Myc antibody‐positive and antibody‐negative patients. Anti‐nuclear antibodies were detected in 40% of lung cancer patients and 57% of those with anti‐L‐Myc antibodies. Our data suggest that detection of anti‐L‐Myc antibodies may be helpful in the diagnosis and evaluation of the host‐immune response to L‐Myc in a subset of lung cancer patients. © 1996 Wiley‐Liss, Inc.